Dave Thomas

Vice President of Industry Research, Biotechnology Innovation Organization

Before joining the leadership team at the Biotechnology Innovation Organization (BIO), Thomas covered investment, research and development, alliance deal trends, as well as regulatory statistics that affect policy initiatives in Washington, D.C.

Prior to joining BIO, Thomas spent more than a decade in the biotech industry as a biochemist in drug discovery at Amgen, Millennium and Novartis, and later in synthetic biology at the J Craig Venter Institute. Thomas is also a financial analyst specializing in risk-adjusted DCF models and holds the Chartered Financial analyst (CFA) designation.